What an interesting study, especially the findings relating to patient biomarkers and predicted therapeutic responsiveness.
A few questions arose for me: 1) for the swabbing procedure, how were the affected areas chosen? Were they on similar body parts/skin types? Did this differ for psoriatic or eczematic skin? This information in the Methods section could be informative for readers. 2) Did you test for intra-patient proteomic consistency by sampling more than once per patient? I'm interested in how intra- and inter-patient heterogeneity might differ from each other, affect clustering, or inform overall conclusions. 3) Similarly, could you compare to swabs/proteomics from non-affected skin areas from the same patients? 4) How do you think disease progression dynamics might also introduce noise in proteomics, i.e. could some of the differences in results be explained by sampling from different timepoints?